Janssen Research & Development, LLC
Why trials sponsored by Janssen Research & Development, LLC stopped, in this sample of ClinicalTrials.gov.
18 stopped trials with a clear reason; 78% ended for non-scientific reasons.
| Reason | Trials | Share |
|---|---|---|
| funding business | 11 | 61% |
| futility | 3 | 17% |
| manufacturing supply | 1 | 6% |
| regulatory | 1 | 6% |
| slow accrual | 1 | 6% |
| safety | 1 | 6% |
Trials
- A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias
NCT05521087 · WITHDRAWN · funding business
“Business Decision” - A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)
NCT06881251 · TERMINATED · futility
“Terminated: futility criteria met at interim efficacy analysis.” - A Study of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection
NCT05784129 · TERMINATED · funding business
“Janssen made an internal business decision to discontinue the PROGRESS study. This decision is not related to any efficacy or safety concerns.” - A Study of JNJ-64304500 Following Subcutaneous Injection in Healthy Chinese Adult Participants
NCT04712006 · WITHDRAWN · funding business
“Sponsor Decision.” - A Study of Itraconazole in the Management of Superficial Fungal Infections in India
NCT03923010 · TERMINATED · funding business
“Further recruitment not possible due to COVID 19 impact. Hence a decision to close study was taken by the sponsor in Aug 2020” - A Study of JNJ-64140284 Solid Dose Formulations in Healthy Male Participants
NCT04033458 · TERMINATED · funding business
“stopped because of a business decision” - Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection
NCT03656510 · TERMINATED · funding business
“Janssen made the strategic decision to discontinue the CROCuS study. This decision is not based on any safety concerns.” - A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-56022473 in Subjects With Systemic Lupus Erythematosus
NCT02920424 · WITHDRAWN · funding business
“The decision is based on a change in the benefit risk assessment of this drug for the lupus population targeted in this study.” - A Long Term Follow-up Study in Participants Treated in a Preceding Phase 2 or 3 Study With a Regimen Containing Odalasvir and AL-335 With or Without Simeprevir for the Treatment of Hepatitis C Virus (HCV) Infection
NCT03099135 · TERMINATED · funding business
“Recruitment prematurely stopped based on decision to stop HPC program (not due to safety or efficacy results) + On 31 Jan 2018 decision to stop the study” - A Prospective Compliance Registry for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT02905201 · WITHDRAWN · funding business
“The protocol was cancelled due timelines be not compatible with business strategy in Colombia.” - Safety & Immunogenicity of JNJ-64041757, Live-attenuated Double-deleted Listeria Immunotherapy, in Subjects With Non Small Cell Lung Cancer
NCT02592967 · TERMINATED · funding business
“Development of JNJ-64041757 discontinued due to lack of efficacy. No further follow up data will be collected after October 22, 2018.” - A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis
NCT02437162 · TERMINATED · safety
“Neither dose achieved the study's primary or major secondary endpoints. The safety profile was consistent with previous ustekinumab studies.” - An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
NCT02413489 · TERMINATED · slow accrual
“DLBCL and FL cohorts met the pre-specified futility criteria and will not proceed. The MCL cohort was terminated due to slow recruitment and aggressive disease.” - Study to Examine the Cytokine Levels, Gene Expression and Safety of a Single Nasal Dose of JNJ-43260295, in Healthy Participants, and Atopic Participants With Mild to Mild-Persistent Asthma
NCT02243189 · TERMINATED · manufacturing supply
“Under enrollment and IP supply expiring.” - A Study to Investigate Evoked Potentials as Markers of Ketamine-induced Cortical Plasticity in Patients With Major Depressive Disorder
NCT01957410 · TERMINATED · futility
“Clinical Team decision to terminate the study after the results from Cohort 1 did not support conducting Cohort 2.” - A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome
NCT01513317 · TERMINATED · futility
“The study was stopped after the interim analysis based on lack of sufficient efficacy. There were no safety concerns.” - A Safety and Tolerability Study of Doripenem Compared With Meropenem in Children Hospitalized With Complicated Intra-abdominal Infections
NCT01110382 · TERMINATED · funding business
“Trial terminated early per business decision” - Safety and Efficacy of EVT 101 in Treatment-Resistant Depression
NCT01128452 · TERMINATED · regulatory
“Evotec has indicated that this study was discontinued due to a clinical hold issued by the FDA”
Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.